IRE1α-XBP1s Axis Regulates SREBP1-dependent MRP1 Expression to Promote Chemoresistance in Non-small Cell Lung Cancer Cells

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2024 Sep 9

PMID 39245881

Authors

Yuzhou Xu

Feng Gui

Zhe Zhang

Zhongyang Chen

Tiange Zhang

Yunhan Hu

Huijun Wei

Yuchen Fu

Xinde Chen

Zhihao Wu

Affiliations

Soon will be listed here.

Abstract

Background: Inositol-requiring enzyme 1 (IRE1) is an endoplasmic reticulum (ER)-resident transmembrane protein that senses ER stress and mediates an essential arm of the unfolded protein response (UPR). IRE1 reduces ER stress by upregulating the expression of multiple ER chaperones through activation of X-box-binding protein 1 (XBP1). Emerging lines of evidence have revealed that IRE1-XBP1 axis serves as a multipurpose signal transducer during oncogenic transformation and cancer development. In this study, we explore how IRE1-XBP1 signaling promotes chemoresistance in lung cancer.

Methods: The expression patterns of UPR components and MRP1 were examined by Western blot. qRT-PCR was employed to determine RNA expression. The promoter activity was determined by luciferase reporter assay. Chemoresistant cancer cells were analyzed by viability, apoptosis. CUT & Tag (Cleavage under targets and tagmentation)-qPCR analysis was used for analysis of DNA-protein interaction.

Results: Here we show that activation of IRE1α-XBP1 pathway leads to an increase in MDR-related protein 1 (MRP1) expression, which facilitates drug extrusion and confers resistance to cytotoxic chemotherapy. At the molecular level, XBP1-induced c-Myc is necessary for SREBP1 expression, and SREBP1 binds to the MRP1 promoter to directly regulate its transcription.

Conclusions: We conclude that IRE1α-XBP1 had important role in chemoresistance and appears to be a novel prognostic marker for lung cancer.

Citing Articles

IRE1α-XBP1s axis regulates SREBP1-dependent MRP1 expression to promote chemoresistance in non-small cell lung cancer cells.

Xu Y, Gui F, Zhang Z, Chen Z, Zhang T, Hu Y Thorac Cancer. 2024; 15(29):2116-2127.

PMID: 39245881 PMC: 11471422. DOI: 10.1111/1759-7714.15442.

References

van Riggelen J, Yetil A, Felsher D . MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; 10(4):301-9. DOI: 10.1038/nrc2819. View

Hetz C, Chevet E, Harding H . Targeting the unfolded protein response in disease. Nat Rev Drug Discov. 2013; 12(9):703-19. DOI: 10.1038/nrd3976. View

Zhang C, Leighl N, Wu Y, Zhong W . Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019; 12(1):45. PMC: 6482588. DOI: 10.1186/s13045-019-0731-8. View

Horton J, Shah N, Warrington J, Anderson N, Park S, Brown M . Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003; 100(21):12027-32. PMC: 218707. DOI: 10.1073/pnas.1534923100. View

Haber M, Smith J, Bordow S, Flemming C, Cohn S, London W . Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol. 2006; 24(10):1546-53. DOI: 10.1200/JCO.2005.01.6196. View

Gouw A, Margulis K, Liu N, Raman S, Mancuso A, Toal G . The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. Cell Metab. 2019; 30(3):556-572.e5. PMC: 6911354. DOI: 10.1016/j.cmet.2019.07.012. View

Sundar R, Cho B, Brahmer J, Soo R . Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015; 7(2):85-96. PMC: 4346216. DOI: 10.1177/1758834014567470. View

Wang M, Kaufman R . The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014; 14(9):581-97. DOI: 10.1038/nrc3800. View

Mao X, Yu C, Yin F, Xu W, Pan Y, Yang B . IRE1α-XBP1 regulates PDK1-dependent induction of epithelial-mesenchymal transition in non-small cell lung cancer cells. Exp Cell Res. 2022; 421(1):113376. DOI: 10.1016/j.yexcr.2022.113376. View

10.

Pajic M, Murray J, Marshall G, Cole S, Norris M, Haber M . ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenet Genomics. 2011; 21(5):270-9. DOI: 10.1097/FPC.0b013e328343dd5f. View

11.

Dong H, Adams N, Xu Y, Cao J, Allan D, Carlyle J . The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. Nat Immunol. 2019; 20(7):865-878. PMC: 6588410. DOI: 10.1038/s41590-019-0388-z. View

12.

Zhao Q, Lin X, Wang G . Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer. Front Oncol. 2022; 12:952371. PMC: 9330218. DOI: 10.3389/fonc.2022.952371. View

13.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

14.

Sheng X, Nenseth H, Qu S, Kuzu O, Frahnow T, Simon L . IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019; 10(1):323. PMC: 6345973. DOI: 10.1038/s41467-018-08152-3. View

15.

Lourenco C, Resetca D, Redel C, Lin P, MacDonald A, Ciaccio R . MYC protein interactors in gene transcription and cancer. Nat Rev Cancer. 2021; 21(9):579-591. DOI: 10.1038/s41568-021-00367-9. View

16.

Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G . Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?. Expert Opin Drug Metab Toxicol. 2011; 7(5):623-42. DOI: 10.1517/17425255.2011.562892. View

17.

Cole S . Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2013; 54:95-117. DOI: 10.1146/annurev-pharmtox-011613-135959. View

18.

Deeley R, Westlake C, Cole S . Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006; 86(3):849-99. DOI: 10.1152/physrev.00035.2005. View

19.

Xu Y, Gui F, Zhang Z, Chen Z, Zhang T, Hu Y . IRE1α-XBP1s axis regulates SREBP1-dependent MRP1 expression to promote chemoresistance in non-small cell lung cancer cells. Thorac Cancer. 2024; 15(29):2116-2127. PMC: 11471422. DOI: 10.1111/1759-7714.15442. View

20.

Geng F, Zhong Y, Su H, Lefai E, Magaki S, Cloughesy T . SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. Cell Rep. 2023; 42(7):112790. PMC: 10528745. DOI: 10.1016/j.celrep.2023.112790. View